Systemic Therapy for Metastatic Colorectal Cancer

Restricted access

In the treatment of advanced colorectal cancer (CRC), the addition of so-called “targeted” agents to irinotecan- and oxaliplatin-based regimens has resulted in statistically significant—but often clinically modest—improvements in progression-free and overall survival. This is true for the most recent additions to the treatment armamentarium, regorafenib and ziv-aflibercept. In his recent presentation at the NCCN 18th Annual Conference, Leonard Saltz, MD, reviewed the landmark trials establishing targeted agents as effective in metastatic CRC. However, he also noted that statistical significance does not necessarily equal clinical significance, and indicated that clinicians should consider the differential toxicity profiles of the regimens when individualizing treatment.

Correspondence: Leonard Saltz, MD, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, Room 1049, New York, NY 10065. E-mail: saltzl@mskcc.org
  • 1.

    AndreTBoniCNavarroM. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:31093116.

    • Search Google Scholar
    • Export Citation
  • 2.

    TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a CERCOR study. J CLin Oncol2006;24:394400.

    • Search Google Scholar
    • Export Citation
  • 3.

    HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 4.

    SaltzLBClarkSDiaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:20132019.

    • Search Google Scholar
    • Export Citation
  • 5.

    BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol2013;14:2937.

    • Search Google Scholar
    • Export Citation
  • 6.

    CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 7.

    Van CutsemEKohneCHHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:14081417.

    • Search Google Scholar
    • Export Citation
  • 8.

    BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663671.

    • Search Google Scholar
    • Export Citation
  • 9.

    DouillardJYSienaSCassidyJ. Final results from PRIME: randomized phase 3 study of panitumumab with FOLFOX4 for 1st-line medical colorectal cancer [abstract]. J Clin Oncol2011;29(Supp 15):Abstract 3510.

    • Search Google Scholar
    • Export Citation
  • 10.

    Van CutsemETaberneroJLakomyR. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer. J Clin Oncol2012;30:34993506.

    • Search Google Scholar
    • Export Citation
  • 11.

    GrotheyAVan CutsemESobreroA. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet2013;381(9863):303312.

    • Search Google Scholar
    • Export Citation
  • 12.

    VakianiEJanakiramanMShenR. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol2012;30:29562962.

    • Search Google Scholar
    • Export Citation
  • 13.

    KopetzDesaiJChanE. PLX4032 in metastatic colorectal cancer patient with mutant BRAF tumors [abstract]. J Clin Oncol2010;28(Suppl 15): Abstract 3534.

    • Search Google Scholar
    • Export Citation
  • 14.

    TejparSBokemeyerCCelikI. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab [abstract]. J Clin Oncol2011;29(Suppl 15): Abstract 3511.

    • Search Google Scholar
    • Export Citation
  • 15.

    PeetersMDouillardJYVan CutsemE. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol2013;31:759765.

    • Search Google Scholar
    • Export Citation
  • 16.

    TolJKoopmanMCatsA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563572.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 148 120 1
PDF Downloads 17 11 1
EPUB Downloads 0 0 0